Spasticity (Spa mouse)

Study novel interventions to improve physical performance in patients affected by muscular Spasticity using the Spa mouse model

Home » Neurology Research Models and Services  » Neuromuscular Disease – Spasticity
Spasticity is associated with increased muscle contraction, causing impaired movement and gait. Spasticity presents in several diseases affecting the neuromuscular system such as Cerebral Palsy, and amyotrophic lateral sclerosis (ALS), or arises due to trauma, such as spinal cord injury and stroke.  

Spasticity can be modelled in Spa mice which have a spontaneous spasticity-associated mutation, resulting in early-onset hypertonia. 

The spasticity mouse used at InnoSer presents symptoms of spasticity at 2 weeks of age and can reach adult age. This makes the spasticity mouse model highly suitable for investigation novel interventions to improve physical performance.  

Take advantage of InnoSer’s expertise in modelling neuromuscular disease pathology, flexibility and collaborative approach for your research. Our in-house neurology experts are happy to help guide your decision on study design fit for your current research goals. 

Spasticity model key characteristics:

  • Spa mice have a hereditary spastic mutation (B6.Cg-Glrbspa/J).
  • Spastic mice display a series of abnormalities, such, including abnormal gait, impaired hind limb motor function, reduced physical activity.
  • Spa mice show skeletal muscle morphology alterations (i.e., muscle mass decrease along with a decrease in the cross-sectional area of myofibers).
  • Model is extensively characterised (published together with Rivares et al, 2020).

Find the right model for you.

Compare our model capabilities and discover which of our neurology platforms suits your research needs

Belgian based preclinical neurology CRO mouse models

Key readouts

Test the efficacy of your treatments with the following commonly used behavioral tests:

Related neuromuscular disease model options

Neurology Platform Overview

Highly relevant neurology models to facilitate preclinical drug development.

CMT1A (C3-PMP22)

InnoSer offers a fee-for-service C-3PMP22 model to research novel therapies against Charcot Marie Tooth Type 1A. 

Duchenne Muscular Dystrophy

Perform behavioural research studies to investigate your novel and innovative targeted Duchenne Muscular Dystrophy therapies.  

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.


Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

Need more information?

If you have any questions about how we can help accelerate your research,

then let us know